Use Case: Application of the Comprehensive Assessment of the Value of Diagnostic Technologies Framework to Exact Sciences Cologuard Multi-target sDNA Test
In response to the growing need to demonstrate how medical technologies fit into the emerging value-based paradigm for providers, payers, and patients, AdvaMed launched a Strategic Value Initiative to develop an approach to value assessment for medical technologies that can be used by Medical technology companies as well as by health systems, payers, and other stakeholders.
This use case demonstrates the value of Exact Sciences’ Cologuard test across all of the identified value drivers and for a range of stakeholders. Cologuard works by detecting altered DNA or excess hemoglobin in the abnormal cells shed into the colon, where they are picked up by stool. This method can also identify abnormal precancerous cells before they are detectable in the bloodstream.